Jane Oliaro

The University of Melbourne — Australia

Immunology and Microbiology · Life Sciences

32h-index4.5kcitations116works32.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(36), CAR-T cell therapy research(35), Immunotherapy and Immune Responses(19), T-cell and B-cell Immunology(16), Cancer Immunotherapy and Biomarkers(16)

Publications116 total

Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory in mouse xenograft models
Science Translational Medicine·2025· 2 cited
Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery
Nature·2025· 31 citedOpen Access
423 | ctDNA‐DIRECTED INTERVENTION WITH EPCORITAMAB ALONE OR IN COMBINATION WITH LENALIDOMIDE‐RITUXIMAB IS FEASIBLE IN THE EARLY POST‐CAR‐T POPULATION AT HIGH RISK OF RELAPSE
Hematological Oncology·2025Open Access
CRISPR engineering of armored CAR T cells enables tumor restricted payload delivery with enhanced efficacy and safety
2025Open Access
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
New England Journal of Medicine·2025· 35 cited
CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease - an <i>In Vivo</i> Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI
Blood·2024· 2 citedOpen Access
Intracellular zinc protects tumours from T cell-mediated cytotoxicity
Cell Death and Differentiation·2024· 7 citedOpen Access
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
Nature·2024· 179 citedOpen Access
Overexpression of FOXO1 enhances CAR T cell polyfunctionality, metabolic fitness and efficacy against solid tumors
2023Open Access
P-015 A Novel CAR-T cell therapy targeting kappa myeloma antigen for the treatment of multiple myeloma
Clinical Lymphoma Myeloma & Leukemia·2023
Data from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
2023Open Access
Supplementary Video Legends and Figures from BET Inhibition Enhances TNF-Mediated Antitumor Immunity
2023Open Access
Video 2 from BET Inhibition Enhances TNF-Mediated Antitumor Immunity
2023Open Access
Data from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
2023Open Access
Video 1 from BET Inhibition Enhances TNF-Mediated Antitumor Immunity
2023Open Access
Data from BET Inhibition Enhances TNF-Mediated Antitumor Immunity
2023Open Access
Supplementary Table S1 from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
2023Open Access
Video 3 from BET Inhibition Enhances TNF-Mediated Antitumor Immunity
2023Open Access
Video 2 from BET Inhibition Enhances TNF-Mediated Antitumor Immunity
2023Open Access
Video 4 from BET Inhibition Enhances TNF-Mediated Antitumor Immunity
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Kelly M. Ramsbottom(21), Conor J. Kearney(18), Sarah M. Russell(16), Ricky W. Johnstone(13), Stephin J. Vervoort(10), Jessica Michie(10), Edwin D. Hawkins(10), Andrew J. Freeman(9), Paul A. Beavis(9), Phillip K. Darcy(9), John Silke(8), Joseph A. Trapani(8), Emily J. Lelliott(8), Mandy Ludford‐Menting(7), Patrick O. Humbert(7), Ian A. Parish(7), Nicole M. Haynes(6), Nigel J. Waterhouse(5), Imran G. House(5), Ilia Voskoboinik(4)